05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations. Medical apparatus for introducing pharmaceutical
preparations into the human body. Providing online non-downloadable publications in the nature
of training materials in the field of health and medical
information. Pharmaceutical research and development.
PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
5.
METHOD FOR ULTRA PRECISION TOOL WEAR CORRECTION WITH SCALING
The present disclosure is directed to correcting toolpath errors in ultra-precision machining of optical parts and mold inserts. A method includes machining a known optical surface to serve as a reference surface and capturing surface error data of the known optical surface using a metrology instrument. The surface error data may include an error map representing deviations from an intended design of the known optical surface. The method also includes smoothing the error map to reduce noise and highlight deviations, thereby creating a smoothed error map; deriving incident angles at which a cutting tool interacts with the known optical surface. The method also includes converting the smoothed error map into a derived angle space corresponding to the incident angles. The method also includes generating a corrected toolpath based on the derived angle space and applying the corrected toolpath to the machining equipment to correct the surface deviations.
G05B 19/402 - Numerical control [NC], i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of programme data in numerical form characterised by control arrangements for positioning, e.g. centring a tool relative to a hole in the workpiece, additional detection means to correct position
G05B 19/18 - Numerical control [NC], i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of programme data in numerical form
G05B 19/404 - Numerical control [NC], i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of programme data in numerical form characterised by control arrangements for compensation, e.g. for backlash, overshoot, tool offset, tool wear, temperature, machine construction errors, load, inertia
G05B 19/406 - Numerical control [NC], i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of programme data in numerical form characterised by monitoring or safety
An ocular implant including a drug releasing element and having an inlet portion and a Schlemm's canal portion distal to the inlet portion, the inlet portion being disposed at a proximal end of the implant and sized and configured to be placed within an anterior chamber of a human eye, the Schlemm's canal portion being arranged and configured to be disposed within Schlemm's canal of the eye when the inlet portion is disposed in the anterior chamber.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
Aspects of the present disclosure generally relate to bottles, such as eye drop bottles, having (1) a thermoplastic elastomer and (2) a polypropylene homopolymer, a random polypropylene copolymer, a random, heterophasic polypropylene copolymer, or combinations thereof. In at least one embodiment, a bottle includes a cap, a nozzle tip, and a body. The cap is configured to engage a threaded portion of a neck of the body. The body includes a composition including (1) a thermoplastic elastomer and (2) a polypropylene homopolymer, a block or random polypropylene copolymer, a random, heterophasic polypropylene copolymer, or combinations thereof.
The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the thermal stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present invention is directed to an antioxidant ophthalmic emulsion. More particularly, the present invention is directed to an ophthalmic emulsion having a unique combination of ingredients that promotes the transparent property of small oil droplets within the emulsion and promotes the therapeutic delivery capability of the emulsion.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
15.
IDENTIFICATION OF ASPIRATED MATERIAL DURING SURGICAL PROCEDURES
In certain embodiments, a method of identifying a composition of an aspirated material includes: controlling a surgical instrument to aspirate material through a probe that is fluidly connected with a vacuum source in an aspiration path. The method further includes estimating, during aspiration of the material, a flow rate of the material at the probe. The method further includes determining, using one or more sensors disposed along one or both of the aspiration path and infusion path, a change in pressure across the probe during aspiration. The method further includes determining a fluidic resistance of the material using the flow rate and the change in pressure, and providing feedback based, at least in part, on the fluidic resistance of the material and a reference value.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
In certain embodiments, a method of identifying a composition of an aspirated material includes: controlling a surgical instrument to aspirate material through a probe that is fluidly connected with a vacuum source in an aspiration path. The method further includes estimating, during aspiration of the material, a flow rate of the material at the probe. The method further includes determining, using one or more sensors disposed along one or both of the aspiration path and infusion path, a change in pressure across the probe during aspiration. The method further includes determining a fluidic resistance of the material using the flow rate and the change in pressure, and providing feedback based, at least in part, on the fluidic resistance of the material and a reference value.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
An apparatus for eye surgery comprising a housing comprising a key track, a bore through the housing, a plunger at least partially disposed in the bore, and a plunger key. The plunger may comprise a rail and a keyway, and the plunger key may comprise a key guide coupled to the key track, an arm coupled to the key guide, and a rail slot through the arm. The arm may be disposed through the keyway of the plunger to allow the arm to move along the key track from a first position to a second position. The arm may be configured to block the rail in the first position and to align the rail slot with the rail in the second position so that the rail can move through the rail slot.
The invention provides methods of using a population of CD19 CAR-expressing cells (for example, rapcabtagene autoleucel) for treating myasthenia gravis. Also disclosed are methods of making a population of CD19 CAR-expressing cells.
In certain embodiments, an ophthalmic system describes the tear film of an eye. A pattern illuminator directs a pattern of light towards the anterior surface of the eye, which reflects the pattern of light. Cameras (including an off-axis camera) generate images of the reflected pattern. A computer performs the following for multiple iterations to yield descriptor sets of the tear film: receive the images of the reflected pattern; determine a tear film value for each image point of each image to yield tear film values for each surface point of the eye; determine a tear film descriptor from the tear film values for each surface point to yield tear film descriptors for the surface points; and generate a descriptor set from the tear film descriptors of the surface points of the eye. The computer generates a tear film description using the descriptor sets.
A method for generating a dark-field inspection image of an ophthalmic lens includes acquiring at least a first dark-field image, a second dark-field image, and a third dark-field image of the ophthalmic lens, determining a brightness value of each pixel of the at least first, second, and third dark-field images, comparing the determined brightness value of each corresponding pixel of the at least first, second, and third dark-field images and determining for each of the corresponding pixels a lowest brightness value, and generating the dark-field inspection image by setting the brightness value of a pixel of the dark-field inspection image to a brightness value representative of a dark pixel in case the determined lowest brightness value is representative of a dark pixel, otherwise setting the brightness value of the pixel of the dark-field inspection image to a brightness value representative of a bright pixel.
This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
31.
DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE
Disclosed are, inter alia, double stranded RNAi (dsRNAi) agents inhibiting expression of proprotein convertase subtilisin kexin 9 (PCSK9), for example, human PCSK9, compositions including the same, and methods of treatment using the same.
The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the thermal stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention is directed to an antioxidant ophthalmic emulsion. More particularly, the present invention is directed to an ophthalmic emulsion having a unique combination of ingredients that promotes the transparent property of small oil droplets within the emulsion and promotes the therapeutic delivery capability of the emulsion.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
34.
MULTI-PART INTRAOCULAR LENS WITH LOCKING MECHANISM
A multi-part intraocular lens (IOL) with an interchangeable optic seated on a base and secured by a locking mechanism. The optic comprises an anterior surface with a diameter greater than a diameter of a ring of the base. The posterior side of the optic has a posterior surface, a transition region for contact with the base, and sidewalls and tabs radially outward of the transition region. The sidewalls and tabs overlap at least a portion of the ring to reduce or even prevent decentration and tilt of the optic. Each tab has a lateral extension for coupling to the base.
Disclosed are, inter alia, double stranded RNAi (dsRNAi) agents inhibiting expression of proprotein convertase subtilisin kexin 9 (PCSK9), for example, human PCSK9, compositions including the same, and methods of treatment using the same.
Disclosed are, inter alia, therapeutic dsRNAi agents with at least one TNA clamp on the sense strand for use in silencing a target gene in a cell or in a subject.
In certain embodiments, an ophthalmic system includes a camera system and a computer. The camera system obtains eye images of an eye (that has an eyelid) during an imaging period. The computer system receives the eye images of the eye from the camera system and extracts a column image from each eye image of the eye images to yield column images. Each column image has a respective longitudinal axis substantially parallel to a vertical axis of the eye. Each column image shows at least the eyelid of the eye at a respective time during the imaging period. The computer system generates a time sequence image from the column images. The time sequence image comprises the column images in temporal order and indicates the position of the eyelid at respective times during the imaging period. The computer system outputs a blink analysis output that includes the time sequence image.
An apparatus for use in the inspection of an ophthalmic lens comprises:
An apparatus for use in the inspection of an ophthalmic lens comprises:
a cubic transparent inspection cuvette, the cuvette comprising walls defining a cubic cuvette interior space and a rectangular cuvette top opening;
An apparatus for use in the inspection of an ophthalmic lens comprises:
a cubic transparent inspection cuvette, the cuvette comprising walls defining a cubic cuvette interior space and a rectangular cuvette top opening;
a filling a placement funnel comprising a funnel top opening and a rectangular funnel bottom opening, and further comprising a seal;
An apparatus for use in the inspection of an ophthalmic lens comprises:
a cubic transparent inspection cuvette, the cuvette comprising walls defining a cubic cuvette interior space and a rectangular cuvette top opening;
a filling a placement funnel comprising a funnel top opening and a rectangular funnel bottom opening, and further comprising a seal;
a cuvette holder; and
An apparatus for use in the inspection of an ophthalmic lens comprises:
a cubic transparent inspection cuvette, the cuvette comprising walls defining a cubic cuvette interior space and a rectangular cuvette top opening;
a filling a placement funnel comprising a funnel top opening and a rectangular funnel bottom opening, and further comprising a seal;
a cuvette holder; and
a funnel holder.
An apparatus for use in the inspection of an ophthalmic lens comprises:
a cubic transparent inspection cuvette, the cuvette comprising walls defining a cubic cuvette interior space and a rectangular cuvette top opening;
a filling a placement funnel comprising a funnel top opening and a rectangular funnel bottom opening, and further comprising a seal;
a cuvette holder; and
a funnel holder.
Cuvette holder may hold cuvette at a cuvette filling and placement orientation,
An apparatus for use in the inspection of an ophthalmic lens comprises:
a cubic transparent inspection cuvette, the cuvette comprising walls defining a cubic cuvette interior space and a rectangular cuvette top opening;
a filling a placement funnel comprising a funnel top opening and a rectangular funnel bottom opening, and further comprising a seal;
a cuvette holder; and
a funnel holder.
Cuvette holder may hold cuvette at a cuvette filling and placement orientation,
Funnel holder may hold funnel at a funnel filling and placement orientation at which a funnel outlet axis coincides with longitudinal axis of cuvette interior space.
An apparatus for use in the inspection of an ophthalmic lens comprises:
a cubic transparent inspection cuvette, the cuvette comprising walls defining a cubic cuvette interior space and a rectangular cuvette top opening;
a filling a placement funnel comprising a funnel top opening and a rectangular funnel bottom opening, and further comprising a seal;
a cuvette holder; and
a funnel holder.
Cuvette holder may hold cuvette at a cuvette filling and placement orientation,
Funnel holder may hold funnel at a funnel filling and placement orientation at which a funnel outlet axis coincides with longitudinal axis of cuvette interior space.
Cuvette holder and funnel holder are movable relative to each other to a filling and placement connection position, in which a liquid-tight connection between funnel bottom opening and cuvette top opening is formed by means of the seal.
In certain embodiments, an ophthalmic system describes the tear film of an eye. A pattern illuminator directs a pattern of light towards the anterior surface of the eye, which reflects the pattern of light. Cameras (including an off-axis camera) generate images of the reflected pattern. A computer performs the following for multiple iterations to yield descriptor sets of the tear film: receive the images of the reflected pattern; determine a tear film value for each image point of each image to yield tear film values for each surface point of the eye; determine a tear film descriptor from the tear film values for each surface point to yield tear film descriptors for the surface points; and generate a descriptor set from the tear film descriptors of the surface points of the eye. The computer generates a tear film description using the descriptor sets.
A method for generating a dark-field inspection image of an ophthalmic lens includes acquiring at least a first dark-field image, a second dark-field image, and a third dark-field image of the ophthalmic lens, determining a brightness value of each pixel of the at least first, second, and third dark-field images, comparing the determined brightness value of each corresponding pixel of the at least first, second, and third dark-field images and determining for each of the corresponding pixels a lowest brightness value, and generating the dark-field inspection image by setting the brightness value of a pixel of the dark-field inspection image to a brightness value representative of a dark pixel in case the determined lowest brightness value is representative of a dark pixel, otherwise setting the brightness value of the pixel of the dark-field inspection image to a brightness value representative of a bright pixel.
An automated production line for the production of ophthalmic lenses comprises:
a production line front end (1) comprising:
a first injection-molding machine (10) and a second injection-molding machine (12)
a casting module (14) comprising
a filling station (144) and a capping station (145);
a stacking module (15) and a curing module (16);
a destacking module (17) and a demolding and delensing module
a production line back end (2) comprising:
a scalable treatment module (20);
an inspection module (21);
a primary packaging module (22),
Wherein the first and second injection-molding machines allow for a quick exchange of the tooling plates used in the injection molding machine without the need to decrease the temperature of the injection molding machine by pre-configured tooling plates.
The present disclosure is directed to contact lenses configured to prevent or slow development of myopia. In some embodiments, a contact lens for slowing the progression of myopia includes a circular first zone extending from an optical center of the contact lens to a first boundary. The first zone has a first visible light transmission profile. The contact lens includes an annular second zone abutting the first zone at the first boundary. The annular second zone at least partially surrounds the first zone and extends from the first boundary to a second boundary. The second zone has the same dioptric power as a dioptric power of the first zone. The second zone has a second visible light transmission profile that is different than the first transmission profile and is a blue light transmission profile.
The disclosure relates to a molecule that inhibits BAFF pathway, particularly an antibody or a binding fragment thereof, particularly an anti-BAFF-R antibody, e.g. ianalumab, for use in the treatment of autoimmune hemolytic anemia (AIHA), in particular, warm autoimmune hemolytic anemia (wAIHA).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The Trustees of the University of Pennsylvania (USA)
University of Pittsburgh - Of the Commonwealth System of Higher Education (USA)
Inventor
Brogdon, Jennifer
Johnson, Laura Alexandra
June, Carl H.
Loew, Andreas
Maus, Marcela
Scholler, John
Okada, Hideho
Abstract
The invention provides compositions and methods for treating diseases associated with expression of EGFRvII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
In certain embodiments, an ophthalmic system includes a camera system and a computer. The camera system obtains eye images of an eye (that has an eyelid) during an imaging period. The computer system receives the eye images of the eye from the camera system and extracts a column image from each eye image of the eye images to yield column images. Each column image has a respective longitudinal axis substantially parallel to a vertical axis of the eye. Each column image shows at least the eyelid of the eye at a respective time during the imaging period. The computer system generates a time sequence image from the column images. The time sequence image comprises the column images in temporal order and indicates the position of the eyelid at respective times during the imaging period. The computer system outputs a blink analysis output that includes the time sequence image.
A61B 3/14 - Arrangements specially adapted for eye photography
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
49.
SURGICAL CASSETTE TUBING ADAPTER AND SENSING FEATURES
In certain embodiments, a surgical cassette for ophthalmic surgical procedures includes a base and a tubing adapter coupled to the base. At least one pump assembly and one or more valve assemblies are disposed in the base. The base further includes a plurality of first channels in fluid communication with the at least one pump assembly. The surgical cassette may further include one or more sensing regions for facilitating detection of the surgical cassette by a surgical console. The one or more valve assemblies are configured to control fluid communication between the plurality of first channels of the base. The tubing adapter includes a plurality of ports in fluid communication with at least one of the plurality of first channels disposed in the base, wherein each of the plurality of ports is configured to receive a corresponding fluidic tube for coupling the fluidic tube to the surgical cassette.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
An optical component includes a substrate having a first optical surface located opposite a second optical surface with at least one of the first optical surface or the second optical surface including a lenslet array formed therein. The optical component also includes an anti-reflective coating located on the first optical surface, a bandpass filter coating located on the second optical surface, and at least one obscuration located on the substrate. The obscuration is configured to block a transmission of light between the first optical surface and the second optical surface.
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing information about medical and scientific research in the field of radioligand therapy and radioligand imaging via a website Providing health information in the field of radioligand therapy and radioligand imaging
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing information about medical and scientific research in the field of radioligand therapy and radioligand imaging via a website Providing health information in the field of radioligand therapy and radioligand imaging
09 - Scientific and electric apparatus and instruments
16 - Paper, cardboard and goods made from these materials
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Digital media, namely, pre-recorded DVDs, downloadable audio and video recordings, and CDs featuring and promoting information regarding PIK3CA-related overgrowth spectrum; Recorded computer application software for mobile phones, computers and handheld digital electronic devices, namely, software for use in providing medical information, mobile applications and games in the field of PIK3CA-related overgrowth spectrum; Downloadable printable educational course materials in the field of of PIK3CA-related overgrowth spectrum; Downloadable comics; Downloadable computer application software for mobile phones, computers and handheld digital electronic devices, namely, software for use in providing medical information, mobile applications and games in the field of PIK3CA-related overgrowth spectrum; Downloadable video recordings featuring information regarding PIK3CA-related overgrowth spectrum Printed educational materials in the field of PIK3CA-related overgrowth spectrum and printed comics featuring information regarding PIK3CA-related overgrowth spectrum Providing online, non-downloadable, short-form videos in the field of PIK3CA-related overgrowth spectrum via social media websites Providing a website featuring information in the field of the diagnosis and treatment of PIK3CA-related overgrowth spectrum; Providing health information in the field of PIK3CA-related overgrowth spectrum.
A robotic system for performing an ocular surgery includes a robot and an electronic control unit (ECU). The robot includes an end-effector, six or more electric motors connected to or operable for moving six or more links and controllable via the ECU, and all-pose gravity compensation structure. A surgical tool is connected to the end-effector. The robot and surgical tool, in response to electronic control signals from the ECU, perform a surgical task on an eye during the ocular surgery. The ECU includes scaling logic operable for downscaling or limiting a tool force imparted to the eye by the surgical tool and/or a tool velocity of the surgical tool. All-pose gravity compensation minimizes a perceived weight of the surgical tool during the ocular surgery. The robotic system may include a surgeon-operated haptic device/master in which the robot acts as a slave device.
Benzotriazole vinylic monomers having an increased solubility in ophthalmic device material formulations relative to certain other benzotriazole vinylic monomers are disclosed. Such benzotriazole vinylic monomers are useful for fabricating various ophthalmic devices including hydrogel contact lenses such as silicone hydrogel contact lenses and can have a high relative ultraviolet and/or High-energy visible light (UV/HEVL) absorption.
C09B 62/465 - Reactive dyes, i.e. dyes which form covalent bonds with the substrates or which polymerise with themselves with the reactive group not directly attached to a heterocyclic ring the reactive group being an acryloyl group, a quaternised or non-quaternised aminoalkyl carbonyl group, or a (—N)n—CO—A—O—X or (—N)n—CO—A—Hal group, wherein A is an alkylene or alkylidene group, X is hydrogen or an acyl radical of an organic or inorganic acid, Hal is a halogen atom, and n is 0 or 1
B29D 11/00 - Producing optical elements, e.g. lenses or prisms
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
Provided herein are methods of producing anti-CD20 antibodies having ofatumumab sequences using host cell cultures such as non-murine host cell cultures (e.g., Chinese hamster ovary (CHO) host cell cultures), e.g., through glycoengineering (e.g., metabolic glycoengineering and/or genetic glycoengineering). CHO host cells expressing such glycoengineered antibodies, and cultures thereof, are also provided. Also provided herein are compositions and pharmaceutical formulations of such antibodies, and methods of treatment using such antibodies (e.g., methods of treating multiple sclerosis).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods, and therapeutic uses thereof for treating autoimmune diseases or disorders.
The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 35/02 - Antineoplastic agents specific for leukemia
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
71.
COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
C07D 209/40 - Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 451/02 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamineCyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropaneCyclic acetals thereof
An optical component includes a substrate having a first optical surface located opposite a second optical surface with at least one of the first optical surface or the second optical surface including a lenslet array formed therein. The optical component also includes an anti-reflective coating located on the first optical surface, a bandpass filter coating located on the second optical surface, and at least one obscuration located on the substrate. The obscuration is configured to block a transmission of light between the first optical surface and the second optical surface.
Benzotriazole vinylic monomers having an increased solubility in ophthalmic device material formulations relative to certain other benzotriazole vinylic monomers are disclosed. Such benzotriazole vinylic monomers are useful for fabricating various ophthalmic devices including hydrogel contact lenses such as silicone hydrogel contact lenses and can have a high relative ultraviolet and/or High-energy visible light (UV/HEVL) absorption.
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
74.
EYE TRACKER WITH HARDWARE FILTERING AND SOFTWARE SORTING
In certain embodiments, an ophthalmic surgical system that tracks the movement of an eye includes a laser device, a camera, and a computer. The laser device directs a laser beam towards the eye, and the camera captures images of the eye. The computer includes hardware and software. The hardware identifies objects in the images of the eye and determines whether each object is a candidate object according to one or more filtering criteria. A candidate object represents a candidate pupil image of the pupil of the eye. The hardware informs the software of the candidate objects. The software sorts the candidate objects according to one or more sorting criteria and identifies a candidate object as the pupil image according to the sorted candidate objects. The software tracks the movement of the eye using the pupil image.
In certain embodiments, a surgical cassette for ophthalmic surgical procedures includes a base and a tubing adapter coupled to the base. At least one pump assembly and one or more valve assemblies are disposed in the base. The base further includes a plurality of first channels in fluid communication with the at least one pump assembly. The surgical cassette may further include one or more sensing regions for facilitating detection of the surgical cassette by a surgical console. The one or more valve assemblies are configured to control fluid communication between the plurality of first channels of the base. The tubing adapter includes a plurality of ports in fluid communication with at least one of the plurality of first channels disposed in the base, wherein each of the plurality of ports is configured to receive a corresponding fluidic tube for coupling the fluidic tube to the surgical cassette.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
A robotic system for performing an ocular surgery includes a robot and an electronic control unit (ECU). The robot includes an end-effector, six or more electric motors connected to or operable for moving six or more links and controllable via the ECU, and all-pose gravity compensation structure. A surgical tool is connected to the end-effector. The robot and surgical tool, in response to electronic control signals from the ECU, perform a surgical task on an eye during the ocular surgery. The ECU includes scaling logic operable for downscaling or limiting a tool force imparted to the eye by the surgical tool and/or a tool velocity of the surgical tool. All-pose gravity compensation minimizes a perceived weight of the surgical tool during the ocular surgery. The robotic system may include a surgeon-operated haptic device/master in which the robot acts as a slave device.
The present disclosure is directed to contact lenses configured to prevent or slow development of myopia. In some embodiments, a contact lens for slowing the progression of myopia includes a circular first zone extending from an optical center of the contact lens to a first boundary. The first zone has a first visible light transmission profile. The contact lens includes an annular second zone abutting the first zone at the first boundary. The annular second zone at least partially surrounds the first zone and extends from the first boundary to a second boundary. The second zone has the same dioptric power as a dioptric power of the first zone. The second zone has a second visible light transmission profile that is different than the first transmission profile and is a blue light transmission profile.
A method for producing embedded hydrogel contact lenses comprises at least the following steps: obtaining an insert made of a crosslinked polymeric material comprising iniferter moieties covalently attached thereto; placing the insert in a female lens mold half; dosing an amount of a lens-forming composition to immerse the insert in the female lens mold half; closing tightly a male lens mold half onto the top of the female lens mold half halves to form a molding assembly; curing the lens-forming composition in the molding assembly to form an embedded hydrogel lens precursor which comprises a bulk hydrogel material formed the lens-forming composition and the insert that is embedded therein and covalently linked to the bulk hydrogel material.
B29C 39/02 - Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressureApparatus therefor for making articles of definite length, i.e. discrete articles
B29C 39/00 - Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressureApparatus therefor
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
C07D 307/93 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
The disclosure provides compounds of Formulae (I) or (II), or a pharmaceutically acceptable salt thereof, (I), or (II) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.
The disclosure provides compounds of Formulae (I) or (II), or a pharmaceutically acceptable salt thereof, (I), or (II) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61P 31/22 - Antivirals for DNA viruses for herpes viruses
C07D 215/54 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
C07D 241/44 - Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
C07F 9/6584 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
86.
INTRAOCULAR LENSES HAVING CLOSED-LOOP RING HAPTIC STRUCTURES
An ophthalmic device includes an optic including an optic axis and a periphery and a closed-loop ring haptic structure coupled with the optic. The closed loop haptic structure includes a first ring structure having a first characteristic length, a second ring structure having a second characteristic length, and a plurality of connectors coupling the first ring structure and the second ring structure. The first ring structure is positioned adjacent to the periphery of the optic and is coupled to the entire periphery of the optic, and the first characteristic length is less than the second characteristic length.
The invention provides methods of using a population of CD19 CAR-expressing cells (for example, rapcabtagene autoleucel) for treating idiopathic inflammatory myopathies. Also disclosed are methods of making a population of CD19 CAR-expressing cells.
The invention provides methods of using a population of CD19 CAR-expressing cells (for example, rapcabtagene autoleucel) for treating neuroimmune diseases or disorders. Also disclosed are methods of making a population of CD19 CAR-expressing cells.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The invention relates to compounds which inhibit CDK4 (Cyclin-Dependent Kinase 4 or Cell Division protein Kinase 4), and to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, and use of said compounds in the treatment of conditions, diseases and disorders mediated by CDK4.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
90.
CHEMICAL PROCESS FOR PREPARING PHENYLPIPERIDINYL INDOLE DERIVATIVES
HH-indol-4- yl)methyl)piperidin-2-yl))benzoic acid, or a pharmaceutically acceptable salt thereof, and/or intermediates thereof, their use as pharmaceuticals and pharmaceutical compositions and the use of intermediates for preparing a compound of formula (I), or a pharmaceutically acceptable salt thereof.
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 211/46 - Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
In certain embodiments, a wireless illumination device (200, 300, 500) is provided. The wireless illumination device includes a handpiece (202) comprising a light source (216) configured to generate an illumination light, a wireless communication module (218) configured to wirelessly receive signals from a user input device (102, 110), a light source driver (220) in communication with the light source and the wireless communication module, an optical fiber (212) extending from the light source to a distal end (250) of the wireless illumination device, and a power source (222) configured to power the light source, the wireless communication module, and the light source driver. The light source driver is configured to drive generation of the illumination light by the light source based on the signals received from the user input device. The optical fiber is configured to transmit the generated illumination light from the light source to the distal end and into an interior portion (402) of a patient's eye (400).
Certain aspects of the present disclosure provide a contact lens with a stepped-transition diffractive design. An example contact lens has an optical zone on its anterior or posterior surface. The optical zone has a circular diffractive zone that has a stepped-transition diffractive surface profile that provides at least one first refractive optical element and at least one diffractive optical element and optionally an annular refractive zone comprising a second refractive optical element. The at least one diffractive optical element comprises a plurality of concentric annular transition surface zones surrounding a central circular area of the contact lens. The stepped-transition surface profile has a monotonically increasing surface sagitta (SAG) in a direction radiating from the central axis of the contact lens.
This invention relates to methods employing IL-1 beta-ligand/IL-1 receptor disrupting compounds, such as IL-1 beta antibodies or IL-1 receptor antibodies, in the treatment and/or prevention of auto-inflammatory syndromes in mammals, particularly humans.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
94.
PRODUCTION LINE FOR THE PRODUCTION OF OPHTHALMIC LENSES
An automated production line for the production of ophthalmic lenses comprises:
a production line front end comprising:
a first and a second injection-molding machine,
a casting module,
a filling station and a capping station,
a stacking module and a curing module,
a destacking module and a demolding and delensing module
a production line back end comprising:
a treatment module,
and inspection module,
wherein self-driving shuttles in the inspection module can form a queue and act as a buffer for the primary packaging module if an interruption of the primary packaging module and variations of the cycle time in the primary packaging module are buffered so that the extraction module is able to operate largely independently from the upstream and downstream components of the manufacturing line.
The disclosure relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein A, Ra, Rb, R1, and p, are as described herein, as well as compositions and methods of using such compounds.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61K 31/428 - Thiazoles condensed with carbocyclic rings
96.
SYSTEMS AND METHODS FOR REVERSIBLE INTRAOCULAR LENS WITH DIFFERENT SPHERICAL ABERRATION CORRECTIONS
A reversible intraocular lens (IOL) includes an anterior optical surface and a posterior optical surface. The anterior optical surface is configured to face a cornea of a user in a first orientation. The posterior optical surface is configured to face a cornea of a user in a second orientation. The reversible IOL provides a first spherical aberration correction in the first orientation and a second spherical aberration correction in the second orientation. The first spherical aberration correction is different from the second spherical aberration correction. Advantageously the reversible IOL can provide two different spherical aberration corrections based on orientation, two different optical powers based on orientation, a variable shift in spherical aberration based on orientation, a variable shift in optical power based on orientation, an EDOF or increased visual contrast at distance vision based on orientation, correction for higher levels of corneal spherical aberration, and a reduction in photic phenomena.
The invention relates to compounds which inhibit CDK4 (Cyclin-Dependent Kinase 4 or Cell Division protein Kinase 4), and to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, and use of said compounds in the treatment of conditions, diseases and disorders mediated by CDK4.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Certain aspects of the present disclosure provide a contact lens with a stepped-transition diffractive design. An example contact lens has an optical zone on its anterior or posterior surface. The optical zone has a circular diffractive zone that has a stepped-transition diffractive surface profile that provides at least one first refractive optical element and at least one diffractive optical element and optionally an annular refractive zone comprising a second refractive optical element. The at least one diffractive optical element comprises a plurality of concentric annular transition surface zones surrounding a central circular area of the contact lens. The stepped-transition surface profile has a monotonically increasing surface sagitta (SAG) in a direction radiating from the central axis of the contact lens.
B29D 11/00 - Producing optical elements, e.g. lenses or prisms
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
